Full Text Journal Articles by
Author Nicole R Bianco


Find full text journal articles

Wearable Cardioverter Defibrillator-Guided 6-Min Walk Test Performed at Home Is Accurate and Reliable: RESULTS OF THE TRENDS STUDY.

Ashley E Burch, Daniel Scherr, Andreas Rieth, John Griffin, Nicole R Bianco, Tanja Odeneg, Samuel F Sears,

<h4>Purpose</h4>The 6-min walk test (6MWT) is broadly used to evaluate the functional ability of patients with heart failure (HF). The purpose of this study was to evaluate the accuracy and reliability of the wearable cardioverter defibrillator (WCD)-guided 6MWT performed at home by patients with HF versus in-clinic testing.<h4>Methods</h4>Patients (n = ... Read more >>

J Cardiopulm Rehabil Prev (Journal of cardiopulmonary rehabilitation and prevention)
[2020, 40(2):E14-E17]

Cited: 2 times

View full text PDF listing >>

Long-term use of the wearable cardioverter defibrillator in patients with explanted ICD.

Georgy Kaspar, Kumar Sanam, Gunjan Gholkar, Nicole R Bianco, Steven Szymkiewicz, Dipak Shah,

OBJECTIVES:To evaluate the effectiveness of wearable cardioverter defibrillator (WCD) use in protecting patients from sudden cardiac arrest (SCA) while they were treated in nonhospital settings until re-implantation of an Implantable cardioverter-defibrillator (ICD) was feasible. We sought to determine whether the WCD could be successfully utilized long term (≥1 year) after ICD ... Read more >>

Int J Cardiol (International journal of cardiology)
[2018, 272:179-184]

Cited: 2 times

View full text PDF listing >>


The US Experience of the Wearable Cardioverter-Defibrillator in Pediatric Patients.

David S Spar, Nicole R Bianco, Timothy K Knilans, Richard J Czosek, Jeffrey B Anderson,

<h4>Background</h4>Certain pediatric patients are at risk for sudden cardiac death. The wearable cardioverter-defibrillator (WCD) can be used in clinical situations in which implantable cardioverter-defibrillator placement is not ideal. The objectives of the study are to examine the effectiveness, safety, and compliance of the WCD in the identification and treatment of ... Read more >>

Circ Arrhythm Electrophysiol (Circulation. Arrhythmia and electrophysiology)
[2018, 11(7):e006163]

Cited: 2 times

View full text PDF listing >>

Outcomes after asystole events occurring during wearable defibrillator-cardioverter use.

Jackson J Liang, Nicole R Bianco, Daniele Muser, Andres Enriquez, Pasquale Santangeli, Benjamin A D'Souza,

AIM:To examine whether wearable cardioverter defibrillator (WCD) alarms for asystole improve patient outcomes and survival. METHODS:All asystole episodes recorded by the WCD in 2013 were retrospectively analyzed from a database of device and medical record documentation and customer call reports. Events were classified as asystole episodes if initial presenting arrhythmia ... Read more >>

World J Cardiol (World journal of cardiology)
[2018, 10(4):21-25]

Cited: 2 times

View full text PDF listing >>

National experience with long-term use of the wearable cardioverter defibrillator in patients with cardiomyopathy.

Madhab Lamichhane, Joseph C Gardiner, Nicole R Bianco, Steven J Szymkiewicz, Ranjan K Thakur,

<h4>Purpose</h4>The wearable cardioverter defibrillator (WCD) is generally used for short periods of sudden cardiac death (SCD) risk; circumstances may occasionally result in prolonged use (over 1 year). The aim of this study was to determine the benefits and risks of prolonged use in patients with systolic heart failure (HF).<h4>Methods</h4>ZOLL's post-market US ... Read more >>

J Interv Card Electrophysiol (Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing)
[2017, 48(1):11-19]

Cited: 7 times

View full text PDF listing >>

The Wearable Cardioverter Defibrillator in Nonischemic Cardiomyopathy: A US National Database Analysis.

Negar Salehi, Mojdeh Nasiri, Nicole R Bianco, Madalina Opreanu, Vini Singh, Vaibhav Satija, Aravdeep S Jhand, Lilit Karapetyan, Abdul Rahman Safadi, Phani Surapaneni, Ranjan K Thakur,

<h4>Background</h4>The wearable cardioverter defibrillator (WCD) is often used in patients at risk of sudden cardiac death (SCD) who are not yet candidates for an implantable cardioverter defibrillator (ICD). Newly diagnosed cardiomyopathy may be reversible, and a WCD may protect patients during the initial period of risk. We evaluate the benefit ... Read more >>

Can J Cardiol (The Canadian journal of cardiology)
[2016, 32(10):1247.e1-1247.e6]

Cited: 11 times

View full text PDF listing >>

Wearable cardioverter-defibrillator use in patients perceived to be at high risk early post-myocardial infarction.

Andrew E Epstein, William T Abraham, Nicole R Bianco, Karl B Kern, Michael Mirro, Sunil V Rao, Edward K Rhee, Scott D Solomon, Steven J Szymkiewicz,

<h4>Objectives</h4>The aim of this study was to describe usage of the wearable cardioverter-defibrillator (WCD) during mandated waiting periods following myocardial infarction (MI) for patients perceived to be at high risk for sudden cardiac arrest (SCA).<h4>Background</h4>Current device guidelines and insurance coverage require waiting periods of either 40 days or 3 months ... Read more >>

J Am Coll Cardiol (Journal of the American College of Cardiology)
[2013, 62(21):2000-2007]

Cited: 83 times

View full text PDF listing >>

Wearable defibrillator use in heart failure (WIF): results of a prospective registry.

Andrew C Kao, Steven W Krause, Rajiv Handa, Darshak Karia, Guillermo Reyes, Nicole R Bianco, Steven J Szymkiewicz, ,

<h4>Background</h4>Heart failure (HF) patients have a high risk of death, and implantable cardioverter defibrillators (ICDs) are effective in preventing sudden cardiac death (SCD). However, a certain percentage of patients may not be immediate candidates for ICDs, particularly those having a short duration of risk or an uncertain amount of risk. ... Read more >>

BMC Cardiovasc Disord (BMC cardiovascular disorders)
[2012, 12:123]

Cited: 20 times

View full text PDF listing >>

Characteristics and outcomes of peripartum versus nonperipartum cardiomyopathy in women using a wearable cardiac defibrillator.

Mitchell T Saltzberg, Steven Szymkiewicz, Nicole R Bianco,

BACKGROUND: Peripartum cardiomyopathy (PPCM) mortality rates vary between 2% and 56%, with half occurring ≤12 weeks'; postpartum. Although risk factors for PPCM have been identified, predicting sudden cardiac death among PPCM patients remains difficult. This study describes the characteristics and outcomes of PPCM patients and controls referred for a wearable ... Read more >>

J Card Fail (Journal of cardiac failure)
[2012, 18(1):21-27]

Cited: 40 times

View full text PDF listing >>

Wearable defibrillator in congenital structural heart disease and inherited arrhythmias.

Mohan Rao, Ilan Goldenberg, Arthur J Moss, Helmut Klein, David T Huang, Nicole R Bianco, Steven J Szymkiewicz, Wojciech Zareba, Andrew Brenyo, Jonathan Buber, Alon Barsheshet,

Patients with congenital structural heart disease (CSHD) and inherited arrhythmias (IAs) are at high risk of ventricular tachyarrhythmias and sudden cardiac death. The present study was designed to evaluate the short- and long-term outcomes of patients with CSHD and IA who received a wearable cardioverter-defibrillator (WCD) for the prevention of ... Read more >>

Am J Cardiol (The American journal of cardiology)
[2011, 108(11):1632-1638]

Cited: 20 times

View full text PDF listing >>

Tumor-derived exosomes confer antigen-specific immunosuppression in a murine delayed-type hypersensitivity model.

Chenjie Yang, Seon-Hee Kim, Nicole R Bianco, Paul D Robbins,

Exosomes are endosome-derived small membrane vesicles that are secreted by most cell types including tumor cells. Tumor-derived exosomes usually contain tumor antigens and have been used as a source of tumor antigens to stimulate anti-tumor immune responses. However, many reports also suggest that tumor-derived exosomes can facilitate tumor immune evasion ... Read more >>

PLoS One (PloS one)
[2011, 6(8):e22517]

Cited: 66 times

View full text PDF listing >>

B7-1/2, but not PD-L1/2 molecules, are required on IL-10-treated tolerogenic DC and DC-derived exosomes for in vivo function.

Melanie A Ruffner, Seon Hee Kim, Nicole R Bianco, Loise M Francisco, Arlene H Sharpe, Paul D Robbins,

Costimulatory molecules, such as B7-1/2 and PD-L1/2 play an important role in the function of APC. The regulation of the surface levels of costimulatory molecules is one mechanism by which APC maintain the balance between tolerance and immunity. We examined the contributions of B7-1/2 and PD-L1/2 to the function of ... Read more >>

Eur J Immunol (European journal of immunology)
[2009, 39(11):3084-3090]

Cited: 33 times

View full text PDF listing >>

Therapeutic effect of exosomes from indoleamine 2,3-dioxygenase-positive dendritic cells in collagen-induced arthritis and delayed-type hypersensitivity disease models.

Nicole R Bianco, Seon Hee Kim, Melanie A Ruffner, Paul D Robbins,

<h4>Objective</h4>We have demonstrated previously that dendritic cells (DCs) modified with immunosuppressive cytokines, and exosomes derived from DCs can suppress the onset of murine collagen-induced arthritis (CIA) and reduce the severity of established arthritis. Indoleamine 2,3-dioxygenase (IDO) is a tryptophan-degrading enzyme that is important for immune regulation and tolerance maintenance. DCs ... Read more >>

Arthritis Rheum (Arthritis and rheumatism)
[2009, 60(2):380-389]

Cited: 85 times

View full text PDF listing >>

Effective treatment of inflammatory disease models with exosomes derived from dendritic cells genetically modified to express IL-4.

Seon Hee Kim, Nicole R Bianco, William J Shufesky, Adrian E Morelli, Paul D Robbins,

In this study, we demonstrate that genetically modified bone marrow-derived dendritic cells (DC) and exosomes derived from the DC, expressing either secreted IL-4 or membrane-bound IL-4, can reduce the severity and the incidence of established collagen-induced arthritis and inhibit inflammation of delayed-type hypersensitivity (DTH) in mice. The ability of the ... Read more >>

J Immunol (Journal of immunology (Baltimore, Md. : 1950))
[2007, 179(4):2242-2249]

Cited: 89 times

View full text PDF listing >>

Modulation of the immune response using dendritic cell-derived exosomes.

Nicole R Bianco, Seon-Hee Kim, Adrian E Morelli, Paul D Robbins,

Initial studies in our laboratory were focused on the use of dendritic cells (DC) genetically modified to express Th2-derived cytokines (i.e., interleukin [IL]-4 and IL-10) or apoptotic proteins (i.e., Fas Ligand [FasL]) to reduce inflammation in a mouse model of experimentally induced arthritis. Exosomes are nano-sized vesicles (40-100 nm diameter) ... Read more >>

Methods Mol Biol (Methods in molecular biology (Clifton, N.J.))
[2007, 380:443-455]

Cited: 37 times

View full text PDF listing >>

MHC class II+ exosomes in plasma suppress inflammation in an antigen-specific and Fas ligand/Fas-dependent manner.

Seon Hee Kim, Nicole R Bianco, William J Shufesky, Adrian E Morelli, Paul D Robbins,

Exosomes are 50- to 100-nm vesicles that are formed within the late endocytic compartment and released from a variety of cell types. Previously, we demonstrated that exosomes derived from dendritic cells transduced with adenoviral vectors expressing IL-10, IL-4, or Fas ligand (FasL) produce anti-inflammatory exosomes able to reduce inflammation in ... Read more >>

J Immunol (Journal of immunology (Baltimore, Md. : 1950))
[2007, 179(4):2235-2241]

Cited: 55 times

View full text PDF listing >>

Differential induction of quinone reductase by phytoestrogens and protection against oestrogen-induced DNA damage.

Nicole R Bianco, Laura J Chaplin, Monica M Montano,

Quinone reductase (QR) is a phase II detoxification enzyme that plays an important role in detoxifying quinones and may help maintain the antioxidant function of the cell. We have previously observed that QR is up-regulated by anti-oestrogens, but not oestrogen, in breast cancer cells via ERbeta (oestrogen receptor beta) transactivation. ... Read more >>

Biochem J (The Biochemical journal)
[2005, 385(Pt 1):279-287]

Cited: 30 times

View full text PDF listing >>

Estrogen receptor regulation of quinone reductase in breast cancer: implications for estrogen-induced breast tumor growth and therapeutic uses of tamoxifen.

Monica M Montano, Nicole R Bianco, Huayun Deng, Bryan M Wittmann, Laura C Chaplin, Benita S Katzenellenbogen,

Antiestrogens have found widespread use in the treatment of breast cancer (reviewed in ref. 1). There is also interest in the use of tamoxifen as a preventive agent for breast cancer. However, the mechanism for the antitumor effects of antiestrogens is relatively unknown. For the most part it is thought ... Read more >>

Front Biosci (Frontiers in bioscience : a journal and virtual library)
[2005, 10:1440-1461]

Cited: 8 times

View full text PDF listing >>

Functional implications of antiestrogen induction of quinone reductase: inhibition of estrogen-induced deoxyribonucleic acid damage.

Nicole R Bianco, George Perry, Mark A Smith, Dennis J Templeton, Monica M Montano,

Recent studies have shown that the antiestrogens tamoxifen and raloxifene may protect against breast cancer, presumably because of a blockade of estrogen receptor (ER)-mediated transcription. Another possible explanation is that antiestrogen-liganded ER transcriptionally induces genes that are protective against cancer. We previously reported that antiestrogen-liganded ERbeta transcriptionally activates the major ... Read more >>

Mol Endocrinol (Molecular endocrinology (Baltimore, Md.))
[2003, 17(7):1344-1355]

Cited: 28 times

View full text PDF listing >>

Regulation of prothymosin alpha by estrogen receptor alpha: molecular mechanisms and relevance in estrogen-mediated breast cell growth.

Nicole R Bianco, Monica M Montano,

Prothymosin alpha (PTalpha) is a small highly acidic protein found in the nuclei of virtually all mammalian tissues. Its high conservation in mammals and wide tissue distribution suggest an essential biological role. While the exact mechanism of action of PTalpha remains elusive, the one constant has been its relationship with ... Read more >>

Oncogene (Oncogene)
[2002, 21(34):5233-5244]

Cited: 19 times

View full text PDF listing >>



1.0675 s